Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Fruquintinib |
Synonyms | |
Therapy Description |
Fruquintinib (HMPL-013) binds and inhibits VEGFR receptors, 1,2 and 3, resulting in reduced cell proliferation and tumor growth (PMID: 25482937, PMID: 31790382). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fruquintinib | HMPL-013 | VEGFR Inhibitor (Pan) 34 | Fruquintinib (HMPL-013) binds and inhibits VEGFR receptors, 1,2 and 3, resulting in reduced cell proliferation and tumor growth (PMID: 25482937, PMID: 31790382). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04322539 | Phase III | Fruquintinib | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer (FRESCO-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 7 |
NCT03251378 | Phase I | Fruquintinib | The Evaluation of Safety, Tolerability, and Pharmacokinetics for Fruquintinib in Solid Tumors | Active, not recruiting | USA | 0 |